Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3845854 | 0.98 | MAPT (0.47) | MAPTCA2CA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL27626557 | 0.98 | MAPT (0.47) | MAPTCA2CA12CA1CA9 | |
| SCHEMBL2919264 | 0.92 | CA2 (0.50) | MAPTCA2CA12CA1CA9 | |
| Trifluoroacetic Acid SCHEMBL2044334 | 0.87 | PKM (0.46) | MAPTCA2CA12CA1CA9 | |
| SCHEMBL28465070 | 0.86 | MAPT (0.41) | MAPTCA2CA12CA1CA9 | |
| SCHEMBL25703358 | 0.82 | CA2 (0.45) | MAPTCA2CA12CA1CA9 | |
| SCHEMBL282864 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL29701080 | 0.81 | PKM (0.42) | MAPTCA2CA12CA1CA9 | |
| Tert-Butyl Formate SCHEMBL28060441 | 0.81 | TDP1 (0.41) | MAPTCA2CA12CA1CA9 | |
| SCHEMBL8530598 | 0.80 | CA2 (0.43) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046148-A1 | NOVEL PARG INHIBITORS | FORX THERAPEUTICS AG (CH) | 2025-03-06 | — | — | WO | claimed |
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | claimed |
| CN-115806550-A | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-3433249-B1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL SCIENT IND RES (IN) | 2022-11-09 | — | — | EP | claimed |
| US-20220306610-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2022-09-29 | — | — | US | claimed |
| CN-109651297-B | N-benzyl-N-aryl sulfonamide derivative and preparation and application thereof | 杭州壹瑞医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-113226469-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-102625799-A | Heterocyclic compounds and their uses | AMGEN INC | 2012-08-01 | — | — | CN | claimed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | claimed |
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | claimed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | claimed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | claimed |
| US-4348389-A | Quinoxaline adducts useful as anthelmintics | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1982-09-07 | — | — | US | claimed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12612427-B2 | Aryl glucoside derivative, preparation method therefor and application thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| US-4348389-A | Quinoxaline adducts useful as anthelmintics | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1982-09-07 | — | — | US | disclosed |
| US-4147785-A | Method for the treatment of onchocerciasis | Dobbie, Graham J. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4093726-A | HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | MAPT 3761/4885CA2 1795/4885CA12 975/4885 |
| US-20220306610-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | SLC10A2, FABP2, SLC10A1 | MAPT 4094/4885CA2 1499/4885CA12 3331/4885 |
| US-12612427-B2 | Aryl glucoside derivative, preparation method therefor and application thereof | SLC5A1, SLC10A1, SLC5A2 | MAPT 3930/4885CA2 2718/4885CA12 2001/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | MAPT 4823/4885CA2 2797/4885CA12 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.